Finance1 min read

Apollo Hospitals, Aster or Molbio — which is a better bet as healthcare stocks rally up to 4% despite D-Street weakness?

By · Published by Everything Blog

In short

Macquarie raised its price targets for Apollo Hospitals to ₹10,500 and Max Healthcare to ₹1,450, pointing to double-digit upside potential despite broader market weakness. While operational expansion pressures appear to be easing, analysts caution that looming Supreme Court treatment price caps and Apollo 24/7 margin drags remain distinct risks. On the technical front, market analysts identify Aster DM Quality Care as having the most promising chart setup among the rallying cohort.

Key points

  • Healthcare stocks rallied up to 4% as easing operational capacity pressures boosted broad…: Healthcare stocks rallied up to 4% as easing operational capacity pressures boosted broader investor sentiment.
  • Aster DM Quality Care shows the strongest technical chart setup with potential to reach ₹…: Aster DM Quality Care shows the strongest technical chart setup with potential to reach ₹800.
  • Regulatory overhangs persist, notably possible Supreme Court pricing caps on non-oncology…: Regulatory overhangs persist, notably possible Supreme Court pricing caps on non-oncology medical treatments.

Sources checked by our analysis pipeline: 1

Healthcare stocks are in focus on Friday, 20 November, even as broader equity markets remained under pressure. Shares of Molbio Diagnostics, Apollo Hospitals Enterprise and Aster DM Quality Care rose up to 4%, drawing investor attention to the hospital and healthcare space.

The rally in hospital stocks comes after global brokerage Macquarie turned more constructive on the sector, upgrading Apollo Hospitals and Max Healthcare to 'Outperform' from 'Underperform'. The brokerage cited improving earnings prospects, more reasonable valuations and signs that the earnings pressure from the ongoing hospital capacity expansion cycle may be easing, according to media reports.

With newly commissioned beds ramping up at a healthy pace and consensus earnings estimates for the sector appearing to have bottomed out, Macquarie believes the risk-reward equation for select hospital stocks has improved.

According to media reports, Macquarie raised its price target on Apollo Hospitals to ₹10,500 from ₹6,230, implying an upside of around 20% from Thursday's closing price.

The brokerage believes the initial impact on profitability from the hospital industry's expansion cycle is already reflected in valuations. It also expects newly added…

Finance